The use of stem cell therapy to prevent myocardial infarctions is explored in a Comment published in The Lancet.

Harald Arnesen and colleagues from the Ullevål University Hospital, Oslo, Norway, looked at studies published on the relatively new technique of using of autologous cells derived from bone marrow cells ( BMC ) to strengthen cardiac function.
Autologous cells are sourced from the patient they are used to treat.
The authors refer to a trial done in 2002 in which such cells were administered into the heart with encouraging results.

The results of this and several other small uncontrolled studies with the same method were encouraging. However, three randomised trials that tested therapy with BMC were negative for the primary endpoint, improvement in left ventricular ejection-fraction ( LVEF ).

A trial of 204 patients ( REPAIR-AMI ) is also discussed by the Comment authors. Half of these patients were randomised to receive an intracoronary infusion of bone marrow cells, or placebo.
LVEF increased slightly in the placebo group ( 47% to 50% ) and slightly more in the BMC group ( 47% to 54% ). Despite this modest difference, there was a significant reduction in clinical events in the BMC group compared to placebo, namely that the combined risk of death, myocardial infarctions or revascularisation fell by nearly half.
Researchers involved in REPAIR-AMI concluded that the results warranted large-scale trials to study effects of bone marrow cells infusion on morbidity and mortality.

The authors are concerned about this, because they feel that the methods for measurement of LVEF in REPAIR-AMI were not ideal, and that the positive clinical effect in that trial was driven by poor outcome in the placebo group.

Source: The Lancet, 2007

XagenaMedicine_2007